Evidence-based guideline for venous thromboembolism prevention in critically ill patients, including pharmacologic and mechanical prophylaxis, special populations, and monitoring.
A comprehensive, evidence-based clinical guideline for the prevention of venous thromboembolism (VTE) in critically ill adult patients. This resource synthesizes recommendations from the major international critical care, hematology, and thrombosis professional societies — including guideline panels on antithrombotic therapy in hospitalized patients, hematology society VTE prevention panels, critical care medicine and thrombosis/haemostasis joint working groups, and national health technology assessment bodies — into a single integrated reference for intensivists, hospitalists, pharmacists, and advanced practice providers managing patients at risk for deep vein thrombosis (DVT) and pulmonary embolism (PE) in the intensive care unit.1 2 3 4 5 6 7 8
Venous thromboembolism is among the most common preventable complications of critical illness. Without prophylaxis, the incidence of DVT in medical-surgical ICU patients ranges from 25% to 32% by screening ultrasonography, and clinically significant PE occurs in 2% to 8%.1 9 ICU patients accumulate multiple simultaneous VTE risk factors — immobility, central venous catheterization, vasopressor use, mechanical ventilation, sepsis, surgery, and trauma — that create a uniquely high-risk environment. Despite this burden, prophylaxis remains underutilized, with compliance rates at many institutions falling below 80%.10
Recent landmark trials have refined our understanding of optimal prophylaxis strategies. Head-to-head comparisons of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the ICU, dose-intensity studies comparing standard-dose and intermediate-dose anticoagulant prophylaxis, and investigations into the role of mechanical prophylaxis as an adjunct or standalone strategy have substantially updated the evidence base since the publication of major guideline statements.5 6 7 8
This guideline covers VTE risk assessment, pharmacologic prophylaxis (agent selection, dosing, renal and obesity adjustments), mechanical prophylaxis, special ICU populations, heparin-induced thrombocytopenia, inferior vena cava filters, diagnosis of ICU-acquired VTE, anti-Xa monitoring, and quality metrics.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Epidemiology, Risk Factors & Risk Assessment | VTE incidence in critical illness; risk factors (immobility, central lines, vasopressors, surgery, trauma, sepsis, obesity, malignancy, prior VTE); Padua Prediction Score (complete table); Caprini Score (complete table); IMPROVE score; ICU-specific risk considerations |
| Part 2 | Pharmacologic Prophylaxis | LMWH dosing (enoxaparin, dalteparin); UFH dosing; LMWH vs UFH evidence (PROTECT trial); dose-intensity evidence (PREVENT, INSPIRATION trials); renal impairment adjustments; obesity dosing; fondaparinux; anti-Xa monitoring; duration and extended prophylaxis |
| Part 3 | Mechanical Prophylaxis, IVC Filters & Diagnosis of ICU-Acquired VTE | Intermittent pneumatic compression devices; graduated compression stockings; combined vs standalone mechanical prophylaxis; IVC filter indications and complications; screening ultrasound protocols; CTPA for PE; transition from prophylaxis to treatment |
| Part 4 | Special ICU Populations, HIT & Quality Metrics | Traumatic brain injury; spinal cord injury; neurosurgery; burns; acute stroke; cardiac surgery; orthopedic trauma; ECMO; thrombocytopenia; active bleeding; HIT recognition and alternative anticoagulants; pregnancy; obesity pharmacokinetics; quality metrics and compliance |
Kahn SR, Lim W, Dunn AS, et al. “Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest. 2012;141(2 Suppl):e195S-e226S. DOI: 10.1378/chest.11-2296 ↩︎ ↩︎
Gould MK, Garcia DA, Wren SM, et al. “Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest. 2012;141(2 Suppl):e227S-e277S. DOI: 10.1378/chest.11-2297 ↩︎
Schünemann HJ, Cushman M, Burnett AE, et al. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.” Blood Adv. 2018;2(22):3198-3225. DOI: 10.1182/bloodadvances.2018022954 ↩︎
National Institute for Health and Care Excellence. “Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.” NICE guideline [NG89]. Published March 2018, updated August 2019. URL: https://www.nice.org.uk/guidance/ng89 ↩︎
Cook DJ, Meade MO, Guyatt G, et al. “Dalteparin versus Unfractionated Heparin in Critically Ill Patients (PROTECT).” N Engl J Med. 2011;364(14):1305-1314. DOI: 10.1056/NEJMoa1014475 ↩︎ ↩︎
Arabi YM, Al-Hameed F, Burns KEA, et al. “Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis (PREVENT).” N Engl J Med. 2019;380(14):1305-1315. DOI: 10.1056/NEJMoa1816150 ↩︎ ↩︎
Lemos ACB, do Espírito Santo DA, Salvetti MC, et al. “Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID).” Thromb Res. 2020;196:359-366. DOI: 10.1016/j.thromres.2020.09.026 ↩︎ ↩︎
Sadeghipour P, Talasaz AH, Rashidi F, et al. “Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.” JAMA. 2021;325(16):1620-1630. DOI: 10.1001/jama.2021.4152 ↩︎ ↩︎
Geerts WH, Bergqvist D, Pineo GF, et al. “Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).” Chest. 2008;133(6 Suppl):381S-453S. DOI: 10.1378/chest.08-0656 ↩︎
Lau BD, Haut ER. “Practices to prevent venous thromboembolism: a brief review.” BMJ Qual Saf. 2014;23(3):187-195. DOI: 10.1136/bmjqs-2012-001782 ↩︎
VTE prophylaxis in traumatic brain injury, spinal cord injury, neurosurgery, burns, stroke, cardiac surgery, orthopedic trauma, ECMO, thrombocytopenia, active bleeding, pregnancy, and obesity; HIT recognition and alternative anticoagulants; quality metrics and compliance monitoring.
Evidence for intermittent pneumatic compression and graduated compression stockings, IVC filter indications and complications, screening ultrasound protocols, CTPA decision-making, and transition from prophylaxis to treatment.
Complete dosing tables for LMWH, UFH, and fondaparinux in ICU patients, renal and obesity dose adjustments, anti-Xa monitoring, key trial evidence (PROTECT, PREVENT, INSPIRATION), and duration of prophylaxis.
Incidence and pathophysiology of VTE in critically ill patients, comprehensive ICU risk factors, and complete risk assessment scoring systems including Padua Prediction Score, Caprini Score, and IMPROVE Score.